Sutro Biopharma, Inc. (S09.F)
- GlobeNewswire
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
High DAR Dual-Payload ADC Sutro unveils unique cell-free capabilities Proprietary cell-free platform enables the design of next-generation ADCs intended to broaden addressable patient populations STRO-004 (tissue factor ADC) preclinical data has demonstrated greater anti-tumor activity and lower toxicity compared to a benchmark tissue factor ADC Preclinical models highlight potent anti-tumor activity of Sutro dual-payload (ADC2) and immunostimulatory (iADC) ADCs Expects to deliver three Investig
- GlobeNewswire
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody-drug conjugates (ADCs), today announced that on September 16, 2024, the Compensation Committee of Sutro’s Board of Directors granted 60,000 restricted stock units (RSUs) of Sutro common stock to a new employee. The grant was made as an inducement material to the employee’s acceptance of em
- GlobeNewswire
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian cancer and was selected to be the recommended phase 2 dose (RP2D) - - Luvelta in combination with bevacizumab demonstrated encouraging preliminary antitumor activity (35% response rate) across all explored dose ranges - - Expansion at RP2D is ongoing with an additional 23 patients enrolled to date;
